Luc Dirix

Research interests

Publications

• The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

  Critical Reviews in Oncology/Hematology · 2018 · https://doi.org/10.1016/j.critrevonc.2018.12.004

• Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

  Breast Cancer Research and Treatment · 2017 · https://doi.org/10.1007/s10549-017-4537-5

• Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30900-2

• Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30450-3

• International consensus guidelines for scoring the histopathological growth patterns of liver metastasis

  British Journal of Cancer · 2017 · 10.1038/bjc.2017.334

• Landscape of somatic mutations in 560 breast cancer whole-genome sequences

  Nature · 2016 · https://doi.org/10.1038/nature17676

• Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells

  European Urology · 2015 · 10.1016/j.eururo.2015.07.007

• Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management

  Breast Cancer Research · 2015 · 10.1186/s13058-015-0526-y

• Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70069-5

• Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.44.9694

• Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets

  Clinical Cancer Research · 2013 · https://doi.org/10.1158/1078-0432.ccr-12-2549

• Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study

  Clinical Cancer Research · 2011 · https://doi.org/10.1158/1078-0432.ccr-10-1869

• mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients

  Clinical Cancer Research · 2011 · https://doi.org/10.1158/1078-0432.ccr-11-0255

• International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

  Annals of Oncology · 2010 · 10.1093/annonc/mdq345

• Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2008.21.6457

• Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2009.25.8707

• Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2008.26.15_suppl.lba1011

• Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.14.4659

• Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

  Annals of Oncology · 2007 · 10.1093/annonc/mdm442

• First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours

  British Journal of Cancer · 2006 · https://doi.org/10.1038/sj.bjc.6603445

• Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification

  Clinical Cancer Research · 2004 · 10.1158/1078-0432.ccr-04-0063

• Increased Serum Interleukin-8 in Patients with Early and Metastatic Breast Cancer Correlates with Early Dissemination and Survival

  Clinical Cancer Research · 2004 · 10.1158/1078-0432.ccr-04-0812

• Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer

  Annals of Oncology · 2003 · 10.1093/annonc/mdg362

• Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer

  International Journal of Cancer · 2002 · 10.1002/ijc.10833

• Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

  Annals of Oncology · 2001 · 10.1023/a:1008382516636

• Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia

  The Journal of Pathology · 2001 · 10.1002/path.966

• Capecitabine, an Oral Fluoropyrimidine Carbamate With Substantial Activity in Advanced Colorectal Cancer: Results of a Randomized Phase II Study

  Journal of Clinical Oncology · 2000 · 10.1200/jco.2000.18.6.1337

• Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer.

  PubMed · 1998

Current projects

No projects listed.